{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F68a3b1c8-6847-4e90-b187-df3b93482a8e","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/68a3b1c8-6847-4e90-b187-df3b93482a8e\"></iframe>","title":"What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma","description":"\n        <p>Professor Philippe Moreau from the University Hospital of Nantes in France discusses anti-CD38 antibody-based treatment approaches for newly diagnosed and relapsed/refractory multiple myeloma moderated by Dr Neil Love. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/MonoclonalAntibodiesMM23\" rel=\"nofollow\">here</a></p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/c77c3e7a-98c6-4fe5-8fb9-ace96a0516a9/cover.jpg"}